Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.

American journal of hematology·2026
Same author

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

Blood cancer journal·2026
Same author

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Current treatment algorithm: diffuse large B cell lymphoma.

Blood cancer journal·2026

Related Experiment Video

Updated: Apr 12, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.8K

ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?

Grzegorz S Nowakowski1, Myron S Czuczman1

  • 1From the Division of Hematology, Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 21, 2015
PubMed
Summary

Personalized Diffuse Large B-cell Lymphoma (DLBCL) therapy relies on molecular subtypes. Targeting specific DLBCL subtypes shows promise for improved patient outcomes and tailored treatment strategies.

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.7K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.4K

Related Experiment Videos

Last Updated: Apr 12, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.8K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.7K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.4K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL).
  • Many DLBCL patients experience refractory disease or relapse, with poor prognoses.
  • DLBCL exhibits significant heterogeneity, with distinct molecular subtypes impacting treatment response.

Purpose of the Study:

  • To highlight the importance of molecular classification for personalized DLBCL therapy.
  • To review advances in molecular characterization and targeted agents for DLBCL.
  • To discuss the potential of subtype-specific treatments for improving patient outcomes.

Main Methods:

  • Review of current literature on DLBCL molecular subtypes and targeted therapies.
  • Analysis of clinical trial data for novel agents combined with standard chemotherapy (R-CHOP).
  • Focus on molecular characterization techniques and their role in personalized medicine.

Main Results:

  • Two major DLBCL subtypes, Germinal Center B-cell (GCB) and Activated B-cell (ABC), show differential responses to therapy.
  • Aggressive subtypes like double-hit and double-expressor lymphomas are associated with poor prognoses.
  • Early clinical trials combining targeted agents with R-CHOP demonstrate feasibility and encouraging efficacy.

Conclusions:

  • Molecular classification is crucial for prognostication and personalization of DLBCL therapy.
  • Targeted agents offer a foundation for subtype-specific treatment strategies.
  • Personalized therapy based on DLBCL molecular subtypes is an achievable goal with potential to improve outcomes.